33
Participants
Start Date
December 29, 2016
Primary Completion Date
June 6, 2022
Study Completion Date
June 6, 2022
itacitinib
Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
ibrutinib
Memorial Sloan Kettering Cancer Center, New York
Roswell Cancer Center, Buffalo
Geisinger Medical Center, Danville
University of Pennsylvania Health System, Philadelphia
University of Maryland Cancer Center, Baltimore
Georgia Regents Research Institute, Augusta
Mount Sinai Comprehensive Cancer Center, Miami Beach
Toledo Clinic Cancer Centers, Toledo
University of Michigan Cancer Center, Ann Arbor
Michigan State University Breslin Cancer Center, Lansing
St Vincent Frontier Cancer Center, Billings
Tulsa Cancer Center, Tulsa
Houston Methodist Cancer Center, Houston
Mayo Clinic Arizona, Scottsdale
Comprehensive Cancer Center of Nevada, Las Vegas
LAC-USC Medical Center/Kenneth Norris Jr Cancer Hospital, Los Angeles
Pacific Shores Medical Group, Long Beach
City of Hope National Medical Center, Duarte
Moores UC San Diego Cancer Center, San Diego
Northwest Medical Specialists & Research Institute, Puyallup
Regional Cancer Center Associates, LLC, Little Silver
Lead Sponsor
Incyte Corporation
INDUSTRY